# Iomai Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iomai

- Industry: Biotechnology
- Headquarters: Gaithersburg, US
- Website: www.iomai.com
- Total disclosed funding: $54M
- Latest round: Series C (Jan 3, 2003)
- Investors on record: 8

## About

Iomai Corporation is a biopharmaceutical company focused on developing innovative vaccines and treatments to enhance immune responses. They specialize in transdermal delivery systems that improve vaccine effectiveness and patient compliance.Founded in 1997 in Gaithersburg, US, Iomai Corporation specializes in vaccine development, particularly using transdermal patches. The company underwent a significant change when it transitioned to focus on vaccine delivery technologies. Iomai's operations were bolstered by a successful TRADE SALE that resulted in raising USD 116.00 mn from Intercell AG in February 2006, marking its latest funding round and total amount raised.Iomai Corporation specializes in developing transdermal vaccine delivery systems, which enhance the efficacy of immunizations by providing a more convenient administration method. Their innovative approach aims to overcome challenges in vaccine delivery, potentially transforming how vaccines are received by patients. Iomai's products are targeted at global markets, enhancing immunization practices, particularly in North America and Europe, where there is a substantial need for improved vaccination methods.In the most recent financial year, 2007, Iomai Corporation reported a revenue of USD 10.67 mn. The company also recorded an EBITDA loss of USD 27.51 mn for the same year, reflecting the costs associated with the development and commercialization of its products.Iomai Corporation is focused on expanding its portfolio of transdermal vaccine delivery products, with plans to launch new offerings within the next few years. The company aims to enter emerging markets in Asia and South America by 2008, leveraging recent funding secured from its TRADE SALE to enhance its research and development capabilities. The goal is to utilize these resources to accelerate product development and market entry, aiming to increase their footprint in global vaccine delivery solutions.

## Funding rounds

- Series C, Jan 3, 2003, $54M — Domain Associates, Essex Woodlands, New Enterprise Associates, Technology Partners, CDIB Capital Group, SAM Private Equity, ProQuest Investments, MedImmune Ventures

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series C
- Essex Woodlands (https://capitalatlas.ai/funds/essex-woodlands) — Series C
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series C
- Technology Partners — Series C
- CDIB Capital Group (https://capitalatlas.ai/funds/cdib-capital-group) — Series C
- SAM Private Equity (https://capitalatlas.ai/funds/sam-private-equity) — Series C
- ProQuest Investments (https://capitalatlas.ai/funds/proquest-investments) — Series C
- MedImmune Ventures (https://capitalatlas.ai/funds/medimmune-ventures) — Series C